国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (6): 350-357.doi: 10.3760/cma.j.issn.1673-422X.2019.06.007

• 综述 • 上一篇    下一篇

选择性CDK4/6抑制剂在实体肿瘤治疗中的应用

张百红1岳红云2   

  1. 1解放军联勤保障部队第九四〇医院肿瘤科，兰州730050； 2解放军联勤保障部队第九四〇医院眼科，兰州730050
  • 出版日期:2019-06-08 发布日期:2019-07-11
  • 通讯作者: 张百红，Email: bhzhang1999@126.com E-mail:bhzhang1999@126.com
  • 基金资助:

    甘肃省自然科学基金（1308RJZA181）

Application of selective CDK4/6 inhibitors in solid cancers therapy

Zhang Baihong1, Yue Hongyun2   

  1. 1Department of Oncology, 940th Hospital of Joint Logistics Support Force of People′s Liberation Army, Lanzhou 730050, China; 2Department of Ophthalmology, 940th Hospital of Joint Logistics Support Force of People′s Liberation Army, Lanzhou 730050, China
  • Online:2019-06-08 Published:2019-07-11
  • Contact: Zhang Baihong, Email: bhzhang1999@126.com E-mail:bhzhang1999@126.com
  • Supported by:

    Natural Science Foundation of Gansu Province of China (1308RJZA181)

PDF

683

摘要： 选择性细胞周期素依赖激酶（CDK)抑制剂已用于ER+/HER2-晚期乳腺癌的治疗，在其他实体肿瘤的临床前研究和临床研究也正在进行中。CDK4/6抑制剂在实体肿瘤中显示出良好疗效，未来CDK4/6抑制剂发展的方向是寻找预测标志物、克服耐药和探索联合治疗模式。

关键词: 肿瘤, 细胞周期蛋白质依赖激酶类, 治疗学, 细胞周期

Abstract: Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+/HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are  biomarkers, drug resistance and combined therapy in the future.

Key words: Neoplasms, Cyclin-dependent kinases, Therapeutics, Cell cycle